Wire · opportunities
FDA Panel Backs Galleri Blood Test for More Than 50 Cancers, and What the Vote Means ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 September 2026 · Fusion42 review
The FDA advisory panel voted in favor of the safety, effectiveness, and benefit-risk balance of GRAIL's Galleri multi-cancer blood test, moving it closer to potential FDA approval for adults 50 and older. The test detects DNA signals related to over 50 cancers with high specificity but moderate sensitivity, meaning it supplements rather than replaces existing cancer screening methods.
This Wire brief sits within Fusion42's coverage of Medtech, and 9 sources have reported it between 23 Sep 2026 and 24 Sep 2026.
◆ ◆ The Wire takeaway
Medtech founders in cancer diagnostics must prepare for FDA scrutiny emphasizing supplementing standard tests, not replacing them. You may now engage insurers and providers differently, highlighting Galleri-like tests as early suits to fill screening gaps, but manage patient expectations on sensitivity.
◆ Coverage
9 sources · first reported 23 Sep 2026 · latest 24 Sep 2026
◆ Related on Wire
◆ Topics